Uncover key drivers, emerging technologies, and competitive movements shaping the adeno-associated virus (avv) vectors in gene therapy market from 2026–2035 with trusted insights from The Business Research Company
What was the valuation of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market in 2026, and what figure is it projected to hit by 2030?
The adeno-associated virus (avv) vectors in gene therapy market has experienced swift expansion in recent years. It is projected to increase from $3.16 billion in 2025 to $3.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. The market’s past growth is attributable to advancements in viral vector safety, research into rare genetic disorders, successful clinical gene therapy outcomes, regulatory approvals, and significant academic research investments.
The adeno-associated virus (avv) vectors in gene therapy market is projected to experience swift expansion over the coming years, with its size forecast to reach $6.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.2%. Factors driving this growth during the projection period include the introduction of commercial gene therapies, the increasing need for scalable vector production, the expansion of precision medicine, incentives for orphan drugs, and the rise in global clinical trials. Key trends anticipated for the forecast period encompass the broadening of gene augmentation therapies, a surge in demand for gene treatments targeting rare diseases, advancements in in vivo gene delivery, an increase in commercial-scale vector manufacturing, and an emphasis on achieving sustained therapeutic effectiveness.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp
Which Drivers Are Affecting Market Participation In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
A growing emphasis on gene-based treatments is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market moving ahead. These therapies involve modifying or manipulating genes to address, prevent, or cure illnesses at a molecular level. Progress in genetic research fuels this intensified focus on developing gene-based treatments, given their ability to improve the accuracy and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors play a crucial role in gene therapy by facilitating the creation of gene-based therapies; they safely and effectively transport therapeutic genes into specific cells due to their minimal immune response and capacity for sustained gene expression. For example, in 2023, data from IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, indicated that worldwide expenditure on cell and gene therapies hit $5.9 billion, signifying a 38% rise compared to 2022. Consequently, the heightened emphasis on developing gene-based therapies is propelling the expansion of the adeno-associated virus (AAV) vectors market.
What Segment Categories Are Covered In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Scale of Operation: Preclinical, Clinical, Commercial
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine
What Trends Are Projected To Support The Growth Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
Major companies operating in the adeno-associated virus (AAV) vectors in the gene therapy market are focusing on advanced innovation, such as tailored vector diversity for assay versatility, to enhance target tissue specificity, improve therapeutic efficacy, and accelerate the development of customized gene therapies across various indications. Tailored vector diversity for assay versatility refers to utilizing multiple AAV serotypes or constructs to support various analytical tests and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, introduced new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the growing needs of cell and gene therapy (CGT) development. The portfolio facilitates a smoother transition from early-stage research to GMP-grade production. It helps standardize processes and improve consistency in viral vector manufacturing. This launch addresses a key challenge in scaling CGT programs toward clinical and commercial readiness.
Which Major Industry Participants Are Leading The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?
Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp
Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2026, By The Business Research Company
Adeno Associated Viral Vectors Market Report 2026
Nucleic Acid Based Gene Therapy Market Report 2026
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model